logo

HomeArticlesServicePriceAbout

Menu

Home
Articles
Service
Price
Search
About
logo
logo

Company

AboutTerms of Service Privacy Policy

Social

LinkedIn Twitter Discord

Contact

contact@coresixteen.com coresixteen.com
Company NameCORE16 Inc.
CEODavid Cho
Business Registration Number762-81-03235
officePhone070-4225-0201
Address83, Uisadang-daero, Yeongdeungpo-gu, Seoul, 07325, Republic of KOREA

Test1

article
박재훈투영인 프로필 사진박재훈투영인
Bausch Health (BHC) Q3 Earnings Expected to Decline(Oct 27, 2022)
created At: 2/24/2025
Neutral
Neutral
This analysis was written from a neutral perspective. We advise you to always make careful and well-informed investment decisions.
BHC
Bausch Health Companies
72
0
0
Fact
Q3 2022 expectations for Bausch Health (BHC): EPS forecast: $0.92 (-19.3% YoY) Revenue forecast: $2.09B (-0.9% YoY) Earnings ESP: -4.56% Zacks Rank: #4 (Sell) Recent performance: Q2 2022: Missed EPS by 38.20% Beat consensus in 2 of last 4 quarters EPS estimates revised up 2.35% in last 30 days
Opinion
The combination of negative year-over-year growth, poor Zacks rank, and negative ESP suggests significant near-term challenges. The substantial Q2 earnings miss (-38.20%) and mixed historical performance indicate potential execution issues. The modest upward revision in estimates appears at odds with other negative indicators, potentially setting up for disappointment.
Core Sell Point
: Multiple negative indicators including declining growth, poor Zacks rank, and negative ESP, combined with recent significant earnings miss, suggest high risk of underperformance in Bausch Health's upcoming Q3 earnings report.

Bausch Health (BHC) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on November 3, 2022, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This drugmaker is expected to post quarterly earnings of $0.92 per share in its upcoming report, which represents a year-over-year change of -19.3%.

Revenues are expected to be $2.09 billion, down 0.9% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 2.35% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Bausch?

For Bausch, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -4.56%.On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Bausch will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Bausch would post earnings of $0.89 per share when it actually produced earnings of $0.55, delivering a surprise of -38.20%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

72
0
0
Comments
0
Please leave a comment first